000			01841cam a2200289 4500
020			_a9241207450
035			_a(Sirsi) 9241207450
060			_aQW 800
111	2		_aWHO Expert Committee on Biological Standardization.
245	0	0	_aWHO Expert Committee on Biological Standardization [meeting held in Geneva from 12 to 18 November 1985] : _bthirty-sixth report.
260			_aGeneva : _bWorld Health Organization, _c1987.
300			_a149 p.
440		0	_aWorld Health Organization technical report series ; _vno. 745
500			_aRussian version of nos. 728-749 bound together (barcode no. 00073792).
520	3		_aAnnounces changes in the status or development of 34 biologicals. The report also presents full details on revised requirements for the manufacturing and national control of tuberculins, dried BCG vaccine, and continuous cell lines, followed by amended requirements for inactivated poliomyelitis vaccine and an addendum to the requirements for antimicrobic susceptibility. A concluding section presents data documenting the history of the production of the WHO primary seed of 17D yellow fever virus to be used in the production of vaccine. As with previous reports from this committee, the present work will serve as both an indispensable reference for manufacturers and control authorities and an integral part of WHOs efforts to assure the production of safe, reliable, and potent biologicals.
546			_aeng fre rus spa.
550			_aWHODOC
561			_aWHO monograph
596			_a4
650	0	2	_aBiological products _xstandards.
690			_aPharmacology, Toxicology and Clinical Technology.
710	2		_aWorld Health Organization.
856			_uhttps://apps.who.int/iris/
856			_uhttps://apps.who.int/iris/
008			870427s1987 eng
942			_2NLM _cMONOGRAPH
999			_c15133 _d15133